Literature DB >> 14504812

Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution.

C Lass-Flörl1, E Gunsilius, G Gastl, M Englisch, G Koch, H Ulmer, M P Dierich, A Petzer.   

Abstract

We assessed the impact of prophylaxis with the oral itraconazole solution and amphotericin B solution on fungal colonization and infection in a randomized study among patients with hematological malignancies and neutropenia. Infecting and colonizing Candida strains of patients suffering from candidiasis were genotyped by random amplification of polymorphic DNA (RAPD) analysis. A total of 106 patients were evaluated in this study: 52 patients in the itraconazole and 54 in the amphotericin B arm. During neutropenia fungal colonization in the oropharynx occurred in 11 (19.6%) and 24 (40.6%) and in the rectum in 11 (19.6%) and 23 (38.9%) courses in the itraconazole and amphotericin B groups ( P<0.05), respectively. Candida albicans was the most prevalent species in both study groups. Mixed fungal colonization with Candida krusei and Candida glabrata was increased in the amphotericin B group, yet without clinical importance since infections were due to C. albicans. The occurrence of invasive candidiasis was significantly increased in multicolonized compared to monocolonized patients. In the amphotericin B group 20 and in the itraconazole group 2 neutropenic patients showed multicolonization with Candida spp. ( P<0.05). Overall fungal infections were 3.8% in the itraconazole and 14.8% in the amphotericin B group ( P<0.05). RAPD typing showed oropharynx strains involved in superficial infections in four of five patients. In all four patients with deep fungal infections, it appears that the colonizing rectum strains were identical to infecting strains of Candida spp. Itraconazole solution significantly reduced Candida colonization and infection compared to amphotericin B solution. Most patients remained infected with the colonized strains for the entire study period, irrespective of antifungal prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504812     DOI: 10.1007/s00277-003-0666-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Interventions for preventing oral candidiasis for patients with cancer receiving treatment.

Authors:  J E Clarkson; H V Worthington; O B Eden
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Authors:  Oliver A Cornely; Angelika Böhme; Dieter Buchheidt; Hermann Einsele; Werner J Heinz; Meinolf Karthaus; Stefan W Krause; William Krüger; Georg Maschmeyer; Olaf Penack; Jörg Ritter; Markus Ruhnke; Michael Sandherr; Michal Sieniawski; Jörg-Janne Vehreschild; Hans-Heinrich Wolf; Andrew J Ullmann
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

Review 4.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2013-11-08

Review 5.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2012-02-20

6.  Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia.

Authors:  Maiken Cavling Arendrup; Sofia Sulim; Anette Holm; Lene Nielsen; Susanne Dam Nielsen; Jenny Dahl Knudsen; Niels Erik Drenck; Jens Jørgen Christensen; Helle Krogh Johansen
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

7.  Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.

Authors:  Osamu Imataki; Yoshitsugu Kubota; Hiroaki Ohnishi; Akira Kitanaka; Toshihiko Ishida; Terukazu Tanaka
Journal:  Support Care Cancer       Date:  2010-09-10       Impact factor: 3.603

Review 8.  Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011.

Authors:  Rene-Jean Bensadoun; Lauren L Patton; Rajesh V Lalla; Joel B Epstein
Journal:  Support Care Cancer       Date:  2011-04-10       Impact factor: 3.603

Review 9.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2009-03-18

10.  Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Cho-Hao Lee; Chin Lin; Ching-Liang Ho; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.